Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Letrozole provides longer time to disease progrssion when compared with tamoxifen
November 10th, 2005
Letrozole provides a longer time to disease progrssion when compared to tamoxifen and without increased time with adverse events. According to a study from the United States, "Results from a phase III study of postmenopausal women with advanced breast cancer demonstrated longer time to disease progression for patients taking letrozole versus tamoxifen. This analysis compares the trade-offs between progression-free survival and toxicity." W. Irish and colleagues calculated "Quality-adjusted survival using Q-TWiST (quality-adjusted time without symptoms or toxicity). Survival curves were partitioned into three health states: toxicity (TOX), disease...
Source: Women's Health Weekly (2005-11-10)
|
